Azoospermia Guide

Azoospermia Guide: Definition, Causes, and New Treatment Approaches

Azoospermia is the complete absence of sperm cells in the ejaculate and is seen in approximately 10 to 15% of male infertility cases. The condition is broadly divided into obstructive azoospermia, where sperm production may be normal but sperm cannot reach the ejaculate because of a blockage, and non-obstructive azoospermia (NOA), where the main problem lies in sperm production or maturation within the testis.

Current scientific discussion increasingly focuses not only on finding sperm surgically, but also on whether immature reproductive cells can be supported biologically and guided toward maturation. In this context, the L-HIS Protocol is presented as a new-generation approach designed to reduce reliance on invasive procedures and prioritize biological restoration.

What causes azoospermia?

Azoospermia can result from several overlapping factors. The most frequently described causes include genetic mutations or Y chromosome microdeletions, hormonal imbalance, infections, immunological problems, prior chemotherapy or radiotherapy, and environmental or idiopathic factors. Because the underlying reason changes both prognosis and treatment planning, detailed classification is essential.

• Obstructive azoospermia: sperm production exists, but a blockage prevents sperm from entering the ejaculate.
• Non-obstructive azoospermia: the issue is related to impaired production, maturation arrest, or inadequate spermatogenesis inside the testis.

Why is Micro-TESE being reconsidered?

Micro-TESE has long been used as a surgical sperm retrieval method, but the reported success rate is generally around 30 to 40%. For many patients, especially those in whom no sperm is found, the procedure does not solve the underlying biological problem. Repeated invasive interventions may also damage sperm-producing areas of the testis and can affect future testicular function.

For this reason, a growing treatment philosophy favors “biological restoration first, surgery later,” especially in selected NOA patients who may still have spermatid-stage germ cells present in the testis.

What is the L-HIS Protocol?

The L-HIS Protocol is a treatment model that shifts the focus from surgical retrieval to biological restoration. Its main idea is that even when mature sperm are not detected, younger sperm cells such as spermatids may still be present. With a personalized 3 to 12 month program using hormonal optimization together with phytotherapy support, these immature cells may be encouraged to mature and become usable for IVF-ICSI.

According to the provided treatment framework, positive cellular growth is reported in 78% of previously unsuccessful Micro-TESE patients. Mature sperm may be obtained in 49% of patients, while 29% may reach the Sd4 elongated spermatid stage.

Phases of the L-HIS Protocol

1. Phase 1: Molecular triggering and hormonal optimization (weeks 0-12). The goal is to create the most favorable hormonal environment for spermatogenesis, including testosterone optimization, aromatase inhibition when appropriate, and FSH-based support for Sertoli cell function.
2. Phase 2: Maturation support (weeks 12-16). Hormonal support continues and ejaculate screening begins. In resistant cases, advanced protein-targeted options such as SPO11 or SYCP3-directed approaches may be considered under appropriate conditions.
3. Phase 3: Intensive ejaculate screening (weeks 16-24+). Rare haploid cells are searched through a multi-stage laboratory process described as the “Sarsma Technique.”

How does the protocol support maturation?

The protocol is built on three core biological principles. First, intratesticular testosterone is optimized, since sperm production requires concentrations far above normal serum levels. Second, the STRA8 pathway is targeted as a molecular key that helps immature cells enter meiosis and continue maturation. Third, Sertoli cells are supported, often through FSH-based hormonal strategy, because they provide the structural and nutritional scaffold required for developing germ cells.

Monitoring and follow-up

The treatment process is designed as a monitored pathway rather than a one-time intervention. Baseline tests generally include FSH, LH, total testosterone, estradiol, liver function tests such as ALT and AST, and lipid profile. These are rechecked at weeks 4, 8, and 12 to assess both safety and whether the intended hormonal effect is being achieved. A central target is to maintain the testosterone to estradiol ratio above 10.

Clinical follow-up is also staged. After medication planning, patients are typically reviewed around day 45 and again around day 75 to assess development and update treatment decisions.

Who may be suitable for treatment?

The protocol is primarily presented for non-obstructive azoospermia and for patients who previously underwent unsuccessful Micro-TESE. Candidate groups described in the source material include:

• patients with azoospermia confirmed by at least two semen analyses and evidence of spermatids,
• patients with maturation arrest or hypospermatogenesis on histopathology,
• selected men with Klinefelter syndrome who retain residual testicular function,
• patients with AzF-c or AzF-c+d microdeletions that still preserve spermatid production potential,
• patients with post-chemotherapy or post-radiotherapy recovery evidence,
• idiopathic NOA patients with detectable inhibin B despite high FSH,
• men between 18 and 55 years of age with acceptable liver function tests.

Who is generally not considered suitable?

• patients with complete AzF-a or AzF-b deletions or total AzF loss,
• patients with complete Sertoli Cell Only histology and no detectable spermatids after prior failed surgery,
• patients with serious liver dysfunction or active liver disease,
• patients with psychiatric contraindications to parts of the medication plan.

Pregnancy expectations and IVF use

This treatment model does not primarily aim for natural conception. Instead, once mature sperm or Sd4-level cells are obtained, assisted reproductive treatment such as IVF with ICSI is typically required. Reported pregnancy potential is approximately 40 to 45% when mature sperm are available and around 20% when fertilization is attempted with Sd4-level cells.

Questions and answers

Conclusion

The L-HIS Protocol represents a modern, minimally invasive shift in azoospermia care. Rather than relying exclusively on surgery, it focuses on cellular development, hormonal balance, and structured laboratory follow-up. For carefully selected NOA patients, especially those with prior failed surgical retrieval, this approach offers a meaningful new framework of hope centered on biological restoration.